Biocytogen is Featured in GEN’s Immunotherapy and Cancer Supplement Issue
Developing animal models for immunotherapy is often difficult due to the complexity of the immune system and tumor biology. Showcased in April’s GEN Magazine, Biocytogen presents a line of target-humanized mice models, covering a growing portfolio of immune checkpoints and cytokines alongside its flagship RenMab fully human antibody mouse. Biocytogen has also developed the immunodeficient B-NDG mice and associated tumor models suited for the investigation of in vivo mechanisms behind xeno-GVHD and antibody efficacy.
